ChemoMetec (CHEMM) Q2 2026 earnings summary

Executive summary

• Revenue for H1 2025/26 was DKK 249.0 million, down 1% year-over-year, but up 3% in local currencies, reflecting resilience despite a sharp US market slowdown due to a prolonged government shutdown.

• EBITDA increased by 1% to DKK 136.2 million, with the EBITDA margin rising to 55% from 54% a year earlier.

• XcytoMatic instrument sales grew organically by 60% year-over-year, offsetting declines in other instrument sales.

• The company maintained its full-year guidance for revenue (DKK 565–580 million) and EBITDA (DKK 320–335 million).

Financial highlights

• Gross profit for H1 was DKK 236.2 million, with a gross margin of 95%, up from 92% last year.

• Net profit for H1 was DKK 94.0 million, down from DKK 103.4 million year-over-year.

• Cash flow from operating activities was DKK 90.6 million, up from DKK 88.0 million a year earlier.

• Dividend of DKK 121.8 million was paid out in H1.

Outlook and guidance

• Full-year revenue is expected in the DKK 565–580 million range, with EBITDA in the DKK 320–335 million range.

• Management remains optimistic about long-term growth, especially in cell and gene therapy, despite short-term US market uncertainty.

• Ongoing customer validation and automation transitions may delay some sales.